Mural Oncology plc (MURA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
MURA Chart
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.
Mural Oncology plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LK Lawrence Kam Sonic GP LLC | 166,984 | $816,551.99 | $816,551.76 | -$0.23 | - |
Mural Oncology plc (MURA) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Mural Oncology plc Profile
| Biotechnology Industry | Healthcare Sector | Caroline J. Loew CEO | NASDAQ (NMS) Exchange | IE000LK2BOB4 ISIN |
| IE Country | 116 Employees | - Last Dividend | - Last Split | 16 Nov 2023 IPO Date |
Overview
Mural Oncology plc is a pioneering clinical-stage oncology company established in 2017 and based in Dublin, Ireland. The company is committed to advancing the field of cancer treatment through the discovery and development of innovative immunotherapies. These treatments are designed to enhance the body's immune system to fight cancer more effectively. Mural Oncology's research and development efforts are focused on creating therapies that can treat a variety of cancers, aiming to improve patient outcomes and quality of life.
Products and Services
- Nemvaleukin Alfa for Mucosal Melanoma
This lead product candidate is being developed as a monotherapy for the treatment of mucosal melanoma, a rare and aggressive form of melanoma that occurs on mucous membranes. Nemvaleukin alfa is designed to stimulate the immune system to target and destroy cancer cells more effectively.
- Nemvaleukin Alfa for Platinum-Resistant Ovarian Cancer
In combination with pembrolizumab, nemvaleukin alfa is also being investigated for the treatment of platinum-resistant ovarian cancer. This approach combines the immunostimulatory effects of nemvaleukin alfa with pembrolizumab, a PD-1 blocking antibody, to potentially enhance therapeutic efficacy against this challenging to treat cancer.
- Nemvaleukin Alfa for Cutaneous Melanoma and Advanced Solid Tumors
Further expanding its application, nemvaleukin alfa is undergoing development for the treatment of cutaneous melanoma and advanced solid tumors. This involves studying the compound in different cancer types to potentially broaden its impact in oncology.
- Engineered Interleukin-18 Program
Mural Oncology is working on an engineered interleukin-18 (IL-18) program aimed at producing a novel immunotherapy. By engineering IL-18, the company seeks to create a therapy that can precisely target and activate the immune system against cancer cells.
- Tumor-Targeted Interleukin-12 Program
The development of a tumor-targeted interleukin-12 (IL-12) program represents another innovative approach by Mural Oncology. This strategy focuses on directing the powerful immune-stimulating effects of IL-12 specifically to tumor sites, potentially reducing side effects and improving treatment efficacy against cancer.
